Skip to main content
HRTX logo

HRTX · Heron Therapeutics, Inc.

Track HRTX — free
$0.27 +0.01 (+2.23%)
Market Cap
$50.25M
Shares
190.27M
Volume · Nov 19 3.61M Avg daily vol (3M) 4.54M

Price & Indicators

 

Key stats

Close
$0.26
Open
$0.27
Day range
$0.25–0.28
52-week closing range
$0.26–1.49
Average volume, 30 days
7.2M
Short interest
34.0M · 17.9% of shares · 19.5 days
Short volume, last session
34%
Last earnings
Nov 9, 2026
Latest filing
10-Q · Nov 9
Price history
Jan 2020 to Nov 2026

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 9
Proxy statement DEFA14A
CorMedix agrees to buy substantially all Heron Therapeutics assets

CorMedix agreed to acquire substantially all Heron Therapeutics assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, in a cash and stock transaction. Closing is expected in the first quarter of 2027, subject to stockholder approval, regulatory clearance and other customary conditions.

Read from the first part of this long document
3 source passages
This Schedule 14A relates solely to preliminary communications made prior to furnishing security holders of Heron Therapeutics, Inc., a Delaware corporation (“Heron” or the “Company”) with a proxy statement related to a proposed transaction in which the Company will sell substantially all of its assets to CorMedix Inc., a Delaware corporation (“CorMedix”), other than certain excluded assets, including the Company’s federal income tax net operating loss carryforwards (“NOLs”) and certain other tax attributes, and CorMedix has agreed to acquire those assets and assume certain liabilities of the Company, upon the terms and subject to the conditions set forth in the Asset Purchase Agreement, dated November 8, 2026, by and between the Company and CorMedix (the “Proposed Transaction”). Earlier today, we announced that CorMedix has agreed to acquire substantially all of Heron’s assets, including all four of Heron’s commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — in a cash and stock transaction. We expect the transaction to close in the first quarter of 2027, subject to approval by Heron stockholders, regulatory clearance, and other customary closing conditions. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Heron agrees $145.0 million asset sale to CorMedix

Heron Therapeutics agreed to sell substantially all assets to CorMedix for 14,583,333 shares and $145.0 million cash, plus royalties and earn-outs, with closing expected in the first quarter of 2027.

Revenue $35.25M ▼ 7.8% Net loss $5.01M Diluted EPS -$0.03
Read from the MD&A section
3 source passages
On November 8, 2026, the Company entered into an Asset Purchase Agreement (the "Asset Purchase Agreement") with CorMedix, pursuant to which it has agreed to sell substantially all of its assets to CorMedix, other than certain excluded assets, including its federal income tax net operating loss carryforwards (the "NOLs") and certain other tax attributes, and CorMedix has agreed to acquire those assets and assume certain liabilities of the Company as set forth in the Asset Purchase Agreement (the "Asset Sale"). As consideration for the Asset Sale, CorMedix has agreed to (i) issue to the Company 14,583,333 shares of CorMedix common stock, (ii) pay to the Company a purchase price equal to $145.0 million in cash, subject to certain adjustments for the Company's closing cash and net working capital as set forth in the Asset Purchase Agreement, of which $2.0 million will be deposited into escrow, at the closing of the Asset Sale to secure post-closing adjustments to the cash consideration, which post-closing adjustments may not exceed $10.0 million in either direction, (iii) pay to the Company royalties equal to 5.0% of the amount, if any, by which aggregate annual net sales of CINVANTI, SUSTOL and the products covered by the Company's multi-product Development and License Agreement (the "License Agreement") with Long Grove Pharmaceuticals, LLC, a Delaware limited liability company ("Long Grove"), exceed $25.0 million in each of calendar years 2027, 2028 and 2029, if and when payable, on the terms set forth in the Asset Purchase Agreement, (iv) pay to the Company earn-out payments of $25.0 million if net sales of ZYNRELEF for calendar year 2028 equal or exceed $65.0 million and an additional $30.0 million if such net sales equal or exceed $95.0 million, payable at CorMedix’s election in cash, shares of CorMedix common stock or a combination thereof (provided that any portion that would cause the aggregate shares of CorMedix common stock issued under the Asset Purchase Agreement to exceed 19.9% of the CorMedix common stock outstanding as of the closing of the Asset Sale will be paid in cash), if and when payable, on the terms set forth in the Asset Purchase Agreement and (v) assume certain of the Company's liabilities as specified in the Asset Purchase Agreement. The Asset Sale, which has been unanimously approved by the board of directors of the Company (the "Board"), is currently expected to close in the first quarter of 2027, subject to approval by the Company's stockholders and the satisfaction of other customary closing conditions. Open the document at this passage
Nov 9
Proxy statement DEFA14A
CorMedix Agrees to Buy Substantially All Assets

Heron Therapeutics, Inc. agreed on November 8, 2026 to sell substantially all assets to CorMedix Inc. for $145.0 million cash and 14,583,333 CorMedix shares, plus royalties and contingent earn-out payments, subject to stockholder and regulatory approvals.

Read from the first part of this long document
2 source passages
On November 8, 2026, Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and CorMedix Inc., a Delaware corporation (the “Buyer”), entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company has agreed to sell substantially all of its assets to the Buyer, other than certain excluded assets, including the Company’s federal income tax net operating loss carryforwards (the “NOLs”) and certain other tax attributes, and the Buyer has agreed to acquire those assets and assume certain liabilities of the Company as set forth in the Purchase Agreement (the “Asset Sale” or the “Proposed Transaction”). As consideration for the Asset Sale, the Buyer has agreed to (i) issue 14,583,333 shares of common stock, par value $0.001 per share, of the Buyer (“Buyer common stock”) (the “Stock Consideration”), (ii) pay to the Company a purchase price equal to $145.0 million in cash, subject to certain adjustments for the Company’s closing cash and net working capital as set forth in the Purchase Agreement (the “Cash Consideration”), of which $2.0 million will be deposited into escrow with Citibank, N.A., as escrow agent, at the Closing (as defined below) to secure post-Closing adjustments to the Cash Consideration, which post-Closing adjustments may not exceed $10.0 million in either direction, (iii) pay to the Company royalties equal to 5.0% of the amount, if any, by which aggregate annual net sales of CINVANTI®, SUSTOL® and the products covered by the Company’s multi-product Development and License Agreement exceed $25.0 million in each of calendar years 2027, 2028 and 2029, if and when payable, on the terms set forth in the Purchase Agreement, (iv) pay to the Company earn-out payments of $25.0 million if net sales of ZYNRELEF® for calendar year 2028 equal or exceed $65.0 million and an additional $30.0 million if such net sales equal or exceed $95.0 million, payable at the Buyer’s election in cash, shares of Buyer common stock or a combination thereof (provided that any portion that would cause the aggregate shares of Buyer common stock issued under the Purchase Agreement to exceed 19.9% of the Buyer common stock outstanding as of the closing of the Asset Sale (the “Closing”) will be paid in cash), if and when payable, on the terms set forth in the Purchase Agreement and (v) assume certain liabilities of the Company as specified in the Purchase Agreement. Open the document at this passage
Nov 9
Current report 8-K
CorMedix Therapeutics to acquire substantially all Heron assets

Heron Therapeutics and CorMedix Therapeutics entered a definitive agreement for CorMedix to acquire substantially all of its assets, subject to stockholder approval and customary closing conditions. Q3 2026 net revenue was $35.3 million, versus $38.2 million in Q3 2025.

Financial results
3 source passages
Heron Therapeutics Announces Third Quarter 2026 Financial Results Heron and CorMedix Therapeutics (“CorMedix”) announced that they have entered into a definitive asset purchase agreement under which CorMedix will acquire substantially all the assets of Heron (the “Asset Sale”). The Asset Sale is subject to approval by Heron’s stockholders and other customary closing conditions. Heron generated total net revenue of $35.3 million in Q3 2026, compared to $38.2 million in Q3 2025 and $37.7 million in Q2 2026. Open the document at this passage
Nov 9
Current report 8-K Events of Nov 8
Heron Therapeutics agrees to sell assets to CorMedix

On November 8, 2026, Heron Therapeutics agreed to sell substantially all assets to CorMedix for $145.0 million cash, subject to closing-cash and net-working-capital adjustments, plus 14,583,333 CorMedix shares, subject to stockholder approval.

Entered into a material agreement, Change to shareholders' rights, Regulation FD disclosure Read from the first part of this long document
3 source passages
On November 8, 2026, Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and CorMedix Inc., a Delaware corporation (the “Buyer”), entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company has agreed to sell substantially all of its assets to the Buyer, other than certain excluded assets, including the Company’s federal income tax net operating loss carryforwards (the “NOLs”) and certain other tax attributes, and the Buyer has agreed to acquire those assets and assume certain liabilities of the Company as set forth in the Purchase Agreement (the “Asset Sale” or the “Proposed Transaction”). As consideration for the Asset Sale, the Buyer has agreed to (i) issue 14,583,333 shares of common stock, par value $0.001 per share, of the Buyer (“Buyer common stock”) (the “Stock Consideration”), (ii) pay to the Company a purchase price equal to $145.0 million in cash, subject to certain adjustments for the Company’s closing cash and net working capital as set forth in the Purchase Agreement (the “Cash Consideration”) The Purchase Agreement, the Asset Sale and other transactions contemplated by the Purchase Agreement must also be approved by the holders of a majority of the issued and outstanding shares of the Company’s common stock (“Common Stock”) entitled to vote thereon (the “Company Stockholder Approval”). Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$148.22M
Trailing 12 months
Net income (TTM)
−$21.56M
Trailing 12 months
Revenue growth YoY
-7.8%
Year over year
Operating margin
-5.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-28.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$11.60M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+12.1%
Year over year · more shares
Price change (1Y)
-75.8%
Trailing year
Short interest
17.9%
Latest settlement · 19.5 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 10, 2026
Q2 FY26

TL;DR. Heron reported Q2 net revenue of $37.7 million with strong acute care growth (ZYNRELEF +35% and APONVIE +74% year-over-year), but withdrew its full-year 2026 guidance following a June court decision on CINVANTI patents that threatens potential generic entry. The company reset its Hercules credit facility, reducing principal by up to $17.5 million and resetting covenants through 2027, and is evaluating strategic alternatives.

Bullish
  • + Acute care franchise delivered $15.3 million, up 43.9% year-over-year
  • + ZYNRELEF net revenue grew 35% year-over-year to $11.1 million
  • + APONVIE net revenue grew 74% year-over-year to $4.2 million with 23% NK1 segment share
  • + Hercules credit facility amended with covenants reset through 2027 and up to $17.5 million principal reduction
  • + Adjusted EBITDA improved to $3.2 million from $2.2 million year-over-year
Bearish
  • − Withdrew full-year 2026 guidance of $173-183 million net product sales and $10-20 million adjusted EBITDA
  • − CINVANTI declined 9.7% year-over-year to $21.8 million due to branded competition and faces potential generic entry
  • − ZYNRELEF Q2 performance came in below company expectations
  • − Net loss widened to $5.5 million from $2.4 million year-over-year
  • − Pro forma cash falls to approximately $24.3 million after September payment from $42.7 million

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −58%
below
Price vs 50-day avg −18%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −11%
trailing
6-month return −68%
trailing
YTD return −80%
this year
Relative strength −63%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
17.87% of shares out · ▼ -7.4% MoM · 19.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
159 holders — mid 3-yr range
Squeeze score 66
elevated · 0–100
Fundamentals
Weak
Revenue growth +7%
Y/Y
Gross margin 73%
expanding
EPS growth −33%
Y/Y
Free cash flow $-27.9M
Quant / Vol
risk profile
Very High
Volatility 97%
annualized · 1-yr
Max drawdown −82%
past year
ATR 14.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed May 11, 2026
Net Revenue · 2026 Full-Year Maintained $173M – $183M
Feb 26, 2026 $173M – $183M changed to May 11, 2026 $173M – $183M
prior FY $154.9M midpoint +14.9% Y/Y
Adjusted EBITDA · 2026 Full-Year Maintained $10M – $20M
Feb 26, 2026 $10M – $20M changed to May 11, 2026 $10M – $20M
Guided vs delivered · last 1 settled
Net Revenue 2025 Full-Year
guided $153M – $163M
$154.9M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−58% Bearish
Price vs 50-day avg
−18% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
17.87% of shares out · ▼ -7.4% MoM · 19.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
159 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $1
vs 200-day avg -58% vs 50-day avg -18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Acute Care Net Product Sales $15.13M the three months ended September 30, 2026 filing —
CINVANTI net revenue $62.3M nine months ended September 30, 2026 —
Customer A 38% the three months ended September 30, 2026 filing —
Customer B 32.8% the three months ended September 30, 2026 filing —
Customer C 26.6% the three months ended September 30, 2026 filing —
Oncology Net Product Sales $20.12M the three months ended September 30, 2026 filing —
SUSTOL net product sales 152K the three months ended September 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HRTX
Heron Therapeutics, Inc.
this stock
$50.25M -79.7% +7.4% — 17.9%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
159
% held
65.0%
Net QoQ
-9.8M sh
Top holder
Rubric Capital Management…
Held Float
View
Held by Funds
Fund positions
102
View
Short & Settlement
Short Interest Falling
Shares short
34.0M
Days to cover
19.5d
Change
-2.7M sh
View
Short Volume
Short vol %
34%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
224.1K
Value
$67.2K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
60.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Ashley Hinson Arenholz
Amount
$1.0K–$15.0K
Traded
Mar 31, 2021
View
Financials
Financials
Net income (FY)
$-20.2M
EPS diluted
$-0.12
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 9, 2026
This year
23

Heron Therapeutics agreed to sell substantially all assets to CorMedix for 14,583,333 shares and $145.0 million cash, plus royalties and earn-outs, with closing expected in the first quarter of 2027.

View
Exempt Offerings
Offering
$30.0M
Filed
Aug 1, 2023
View
Earnings & Events
Webcasts
Last webcast
Nov 9, 2026
View
Investor Relations
Latest news
Heron Therapeutics Announces Thir…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
HRTX -19.0% -10.8% -68.2% -4.9% -79.7%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -13.5% -4.6% -62.6% +0.4% -84.7%
Key facts CIK 818033 CUSIP 427746102 13F (30d) 157 filings 141 filers Visit website Investor relations